The role of telomere-related tetraploidization in cancer

端粒相关四倍体化在癌症中的作用

基本信息

  • 批准号:
    8161963
  • 负责人:
  • 金额:
    $ 35.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-15 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This project addresses a key problem in human cancer: the origins of aneuploidy. Aneuploidy is among the hallmarks of human solid tumors and is now recognized as one of the contributing factors in malignant transformation but its origin is not fully understood. While sporadic gains and losses of chromosomes can adequately explain a substantial fraction of the aberrant chromosome numbers, this explanation falls short in the context of cancers with a triploid or near-tetraploid chromosome number. It has been proposed that cancers carrying a high chromosome number originate from an unstable tetraploid intermediate. Tetraploid cells are known to mis-segregate chromosomes at a high rate, generating subclones with the sub-tetraploid or near-triploid chromosome numbers observed in cancer. These considerations have led to a quest to understand the mechanism by which tetraploidy arises during tumorigenesis. Prior to our work, three main mechanisms had been proposed. First, tetraploid cells can arise from (virally-mediated) cell-cell fusion, yielding a bi-nucleated cell which is converted into a tetraploid state during the next cell division. Second, tetraploidy can arise when cells experience a prolonged arrest in mitosis. Depending on the genetic context, mitotic slippage can occur, yielding a cell with a single tetraploid nucleus and two centrosomes in G1. Third, when the cleavage furrow is impeded, either experimentally (actin inhibition) or by a lagging chromosome, cytokinesis fails and tetraploidy arises. While each of these pathways may be operational in some cancers, they are unlikely to be a general aspect of tumorigenesis and do not explain the high frequency of tetraploidization suggested by the large percentage of tumors with a high chromosome number. Based on our preliminary data, we propose a novel mechanism for tetraploidization that involves the DNA damage signal originating from shortened dysfunctional telomeres. It has long been known that most human solid tumors experience a period of telomere shortening before telomerase is upregulated. We propose that the resulting telomere dysfunction generates a DNA damage response that can induce tetraploidization as well as other forms of genome instability, such as the Breakage-Fusion Bridge cycles resulting from dicentric chromosomes. This hypothesis is attractive because it can explain the generality and high frequency of tetraploidization in solid tumors. In addition, the insult driving tetraploidization - telomere dysfunction - is a transient state. The current project is designed to test this new hypothesis. Given the large number of tumors showing evidence of past tetraploidization, our work has the potential to have broad impact on the knowledge of the origins of aneuploidy in cancer. PUBLIC HEALTH RELEVANCE: Most human solid tumors often show aberrant chromosome numbers, a phenomenon referred to as aneuploidy. Aneuploidy is an important factor in the formation of human cancer but it is not understood how aneuploidy arises. This project tests a new hypothesis on the origin of aneuploidy.
描述(由申请人提供):本项目研究人类癌症的一个关键问题:非整倍体的起源。非整倍体是人类实体肿瘤的标志之一,现在被认为是恶性转化的因素之一,但其起源尚不完全清楚。虽然零星的染色体获得和丢失可以充分解释相当一部分异常染色体数目,但这种解释在具有三倍体或近四倍体染色体数目的癌症的背景下是不足的。有人提出,携带高染色体数的癌症起源于不稳定的四倍体中间体。众所周知,四倍体细胞染色体的错误分离率很高,产生亚四倍体或近三倍体染色体数目的亚克隆,在癌症中观察到。这些考虑导致了对四倍体在肿瘤发生过程中产生的机制的探索。在我们开展工作之前,提出了三个主要机制。首先,四倍体细胞可以从(病毒介导的)细胞-细胞融合中产生,产生双核细胞,在下一次细胞分裂时转化为四倍体状态。其次,当细胞在有丝分裂中经历长时间的停滞时,可以产生四倍体。根据遗传环境的不同,有丝分裂可以发生滑移,在G1期产生一个具有单个四倍体核和两个中心体的细胞。第三,当卵裂沟受阻时,无论是实验性的(肌动蛋白抑制)还是滞后染色体,细胞质分裂失败并产生四倍体。虽然这些途径中的每一个可能在某些癌症中起作用,但它们不太可能是肿瘤发生的一般方面,也不能解释高染色体数肿瘤的高百分比所暗示的高频率四倍体化。基于我们的初步数据,我们提出了一个新的四倍体化机制,涉及DNA损伤信号起源于缩短功能失调的端粒。人们早就知道,在端粒酶上调之前,大多数人类实体肿瘤都会经历一段端粒缩短的时期。我们提出,由此产生的端粒功能障碍产生DNA损伤反应,可以诱导四倍体化以及其他形式的基因组不稳定,例如由双中心染色体引起的断裂-融合桥循环。这个假设很有吸引力,因为它可以解释实体肿瘤中四倍体化的普遍性和高频率。此外,驱动四倍体化的损伤-端粒功能障碍-是一种短暂状态。目前的项目旨在验证这一新的假设。鉴于大量肿瘤显示过去四倍体化的证据,我们的工作有可能对癌症非整倍体起源的知识产生广泛的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Titia de Lange其他文献

Titia de Lange的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Titia de Lange', 18)}}的其他基金

Genome instability in cancer: telomeres and DNA repair
癌症中的基因组不稳定性:端粒和 DNA 修复
  • 批准号:
    10736646
  • 财政年份:
    2016
  • 资助金额:
    $ 35.17万
  • 项目类别:
Genome instability in cancer: telomeres and DNA repair
癌症中的基因组不稳定性:端粒和 DNA 修复
  • 批准号:
    9768895
  • 财政年份:
    2016
  • 资助金额:
    $ 35.17万
  • 项目类别:
Genome instability in cancer: telomeres and DNA repair
癌症中的基因组不稳定性:端粒和 DNA 修复
  • 批准号:
    10460645
  • 财政年份:
    2016
  • 资助金额:
    $ 35.17万
  • 项目类别:
Genome instability in cancer: telomeres and DNA repair
癌症中的基因组不稳定性:端粒和 DNA 修复
  • 批准号:
    10006509
  • 财政年份:
    2016
  • 资助金额:
    $ 35.17万
  • 项目类别:
Genome instability in cancer: telomeres and DNA repair
癌症中的基因组不稳定性:端粒和 DNA 修复
  • 批准号:
    10242700
  • 财政年份:
    2016
  • 资助金额:
    $ 35.17万
  • 项目类别:
Genome instability in cancer: telomeres and DNA repair
癌症中的基因组不稳定性:端粒和 DNA 修复
  • 批准号:
    9186655
  • 财政年份:
    2016
  • 资助金额:
    $ 35.17万
  • 项目类别:
Regulation of DSB repair by 53BP1
53BP1 对 DSB 修复的调节
  • 批准号:
    8968823
  • 财政年份:
    2013
  • 资助金额:
    $ 35.17万
  • 项目类别:
Regulation of DSB repair by 53BP1
53BP1 对 DSB 修复的调节
  • 批准号:
    8782612
  • 财政年份:
    2013
  • 资助金额:
    $ 35.17万
  • 项目类别:
The role of telomere-related tetraploidization in cancer
端粒相关四倍体化在癌症中的作用
  • 批准号:
    8320130
  • 财政年份:
    2011
  • 资助金额:
    $ 35.17万
  • 项目类别:
The role of telomere-related tetraploidization in cancer
端粒相关四倍体化在癌症中的作用
  • 批准号:
    8680182
  • 财政年份:
    2011
  • 资助金额:
    $ 35.17万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.17万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了